Skip to: site menu | section menu | main content

Priligy : The Premature Ejaculation Oral Treatment

Information for consumers
Currently viewing: Priligy » Home

Priligy information resource

Navigation:

Latest News
Pharmacological Info
Disclaimer
Back to top
Back to top
This site is an independent website that provides information on Priligy (Dapoxetine). Priligy is a registered trademark. This site is not affiliated with and does not represent in any way whatsoever the trademark holder.
In particular, this site has not been endorsed by Johnson & Johnson, Janssen Pharmaceutic NV or any other holder of the Priligy trademark.

Did you know?

Priligy is the first and only oral treatment developed for the treatment of premature ejaculation.

Priligy is manufactured by the ALZA Corporation, a subsidiary of Johnson & Johnson.

The recommended starting dose of Priligy is 30mg.

The maximum recommended dose of Priligy is 60mg.

Priligy should be taken between one and three hours before sexual activity occurs, and no more than once per day.

Safety and efficacy of Priligy has not been established in patients 65 years and older due to the limited amount of data on this age group.

Priligy (dapoxetine) - The Prescription Drug for the treatment of Premature Ejaculation

priligy (dapoxetine) tabletWelcome to the Priligy information web site. Priligy (generic name dapoxetine), is a prescription medication used as treatment for erectile dysfunction. Priligy has been clinically proven to extend the length of time of sexual intercourse by between 200% and 400%.

Priligy has been approved for sale in Finland, Sweden, Austria, Germany, Italy, Spain and Portugal and it is now approved in the UK and has gone on sale on private prescription.

Premature ejaculation is a very common condition, affecting in the region of 30% of men worldwide

Priligy can be prescribed for you if you are a male aged between 18 and 64 for the treatment of premature ejaculation.

Buy priligy

Priligy in the UK, EU and US

Priligy has been approved for use by health authorities in Finland, Sweden, Austria, Germany, Italy, Spain and Portugal. It has also now been approved for use in the UK.

THE FDA (Food and Drug Administration) have not yet approved Priligy as a treatment for premature ejaculation. Approval was turned down in 2005. However, Johnson and Johnson will be discussing approval options with the U.S. Food and Drug Administration later this year (2009), according to Joanne Waldstreicher, the chief medical officer at Johnson and Johnson. Johnson and Johnson have conducted three additional late stage tests for safety and effectiveness, which have been completed since the 2005 rejection. The latest news is that Priligy is currently in Phase III of the US FDA approval process.

Priligy is prescribed for the treatment of premature ejaculation in men. It is not indicated for use by women.

 

Back to top